300683 Stock Overview
A biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wuhan Hiteck Biological Pharma Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.36 |
| 52 Week High | CN¥51.64 |
| 52 Week Low | CN¥18.80 |
| Beta | -0.36 |
| 11 Month Change | 4.29% |
| 3 Month Change | -6.09% |
| 1 Year Change | -30.21% |
| 33 Year Change | -42.56% |
| 5 Year Change | -30.73% |
| Change since IPO | -52.86% |
Recent News & Updates
Shareholder Returns
| 300683 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.3% | -5.1% | -2.2% |
| 1Y | -30.2% | -21.6% | -18.0% |
Return vs Industry: 300683 underperformed the CN Biotechs industry which returned -21.6% over the past year.
Return vs Market: 300683 underperformed the CN Market which returned -18% over the past year.
Price Volatility
| 300683 volatility | |
|---|---|
| 300683 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300683 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300683's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,520 | Ya Chen | www.hiteck.com.cn |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein.
Wuhan Hiteck Biological Pharma Co.,Ltd Fundamentals Summary
| 300683 fundamental statistics | |
|---|---|
| Market cap | CN¥2.91b |
| Earnings (TTM) | -CN¥132.46m |
| Revenue (TTM) | CN¥600.46m |
4.9x
P/S Ratio-22.1x
P/E RatioIs 300683 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300683 income statement (TTM) | |
|---|---|
| Revenue | CN¥600.46m |
| Cost of Revenue | CN¥359.39m |
| Gross Profit | CN¥241.07m |
| Other Expenses | CN¥373.53m |
| Earnings | -CN¥132.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 40.15% |
| Net Profit Margin | -22.06% |
| Debt/Equity Ratio | 2.0% |
How did 300683 perform over the long term?
See historical performance and comparison